BlackRock Advisors’s Akebia Therapeutics AKBA Stock Holding History

BlackRock Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$193K	Sell	18,554 -558	-3%	-$4.8K	﹤0.01%	2730
2016 Q3	$173K	Buy	19,112 +2,581	+16%	+$21.9K	﹤0.01%	2758
2016 Q2	$124K	Buy	16,531 +676	+4%	+$5.9K	﹤0.01%	2853
2016 Q1	$143K	Buy	15,855 +6,781	+75%	+$55K	﹤0.01%	2730
2015 Q4	$117K	Sell	9,074 -2,619	-22%	-$26.7K	﹤0.01%	2848
2015 Q3	$113K	Sell	11,693 -9,487	-45%	-$87.1K	﹤0.01%	3040
2015 Q2	$218K	Buy	21,180 +17,494	+475%	+$149K	﹤0.01%	2745
2015 Q1	$41K	Buy	3,686 +460	+14%	+$4.9K	﹤0.01%	3294
2014 Q4	$38K	Hold	3,226	–	–	﹤0.01%	3338
2014 Q3	$71K	Sell	3,226 -50,846	-94%	-$1.17M	﹤0.01%	3170
2014 Q2	$1.5M	Buy	+54,072	New	+$1.3M	﹤0.01%	1269

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock Advisors's AKBA Position: Q4 2016 in Review

BlackRock Advisors reduced its Akebia Therapeutics (AKBA) stake by 2.9% in Q4 2016, selling an estimated $4.8K and leaving 18,554 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

BlackRock Advisors first reported a position in AKBA in Q2 2014 and has held it in 11 quarters since. The position peaked at $1.5M in Q2 2014. 95 funds tracked by Wall St. Rank hold AKBA as of Q4 2016.

BlackRock Advisors held 18,554 shares of Akebia Therapeutics worth $193K as of Q4 2016.
BlackRock Advisors sold 558 Akebia Therapeutics shares in Q4 2016, an estimated $4.8K.
Akebia Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2730 holding.
BlackRock Advisors first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Advisors's Akebia Therapeutics position peaked at $1.5M in Q2 2014.
95 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.